Last reviewed · How we verify
Epsilon-aminocaproic acid administered
Epsilon-aminocaproic acid inhibits fibrinolysis by blocking plasminogen activation and plasmin activity, thereby reducing excessive bleeding.
Epsilon-aminocaproic acid inhibits fibrinolysis by blocking plasminogen activation and plasmin activity, thereby reducing excessive bleeding. Used for Prevention and treatment of excessive bleeding associated with fibrinolysis, Perioperative bleeding reduction in surgical patients.
At a glance
| Generic name | Epsilon-aminocaproic acid administered |
|---|---|
| Sponsor | Montefiore Medical Center |
| Drug class | Antifibrinolytic agent |
| Target | Plasminogen / Plasmin |
| Modality | Small molecule |
| Therapeutic area | Hematology / Hemostasis |
| Phase | Phase 3 |
Mechanism of action
This antifibrinolytic agent works by competitively inhibiting the binding of plasminogen and plasmin to fibrin, which prevents the breakdown of blood clots. By stabilizing fibrin clots and reducing fibrinolysis, it decreases bleeding in conditions characterized by excessive fibrinolytic activity, such as during or after surgical procedures or in certain bleeding disorders.
Approved indications
- Prevention and treatment of excessive bleeding associated with fibrinolysis
- Perioperative bleeding reduction in surgical patients
Common side effects
- Thrombosis / thromboembolic events
- Nausea
- Diarrhea
- Headache
- Myopathy
Key clinical trials
- Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)
- Extended Perioperative Administration of Fibrinolysis Inhibitors After Cardiac Surgery (NA)
- Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care
- PRevention Of BLeeding in hEmatological Malignancies With Antifibrinolytic (Epsilon Aminocaproic Acid) (PHASE2)
- Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss After Total Hip Replacement (PHASE2)
- Efficacy of Tranexamic Acid and Epsilon-aminocaproic Acid in Reducing Bleeding and Transfusions in Cardiac Surgery (PHASE3)
- Oral Tranexamic Acid vs. Oral Aminocaproic Acid to Reduce Blood Loss and Transfusion After Total Knee Replacement. (PHASE2)
- TXA vs. Amicar in Total Knee and Hip Arthroplasty (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: